1. Home
  2. MAIN vs GKOS Comparison

MAIN vs GKOS Comparison

Compare MAIN & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAIN
  • GKOS
  • Stock Information
  • Founded
  • MAIN 2007
  • GKOS 1998
  • Country
  • MAIN United States
  • GKOS United States
  • Employees
  • MAIN N/A
  • GKOS N/A
  • Industry
  • MAIN Finance/Investors Services
  • GKOS Medical/Dental Instruments
  • Sector
  • MAIN Finance
  • GKOS Health Care
  • Exchange
  • MAIN Nasdaq
  • GKOS Nasdaq
  • Market Cap
  • MAIN 5.3B
  • GKOS 5.8B
  • IPO Year
  • MAIN 2007
  • GKOS 2015
  • Fundamental
  • Price
  • MAIN $65.09
  • GKOS $94.21
  • Analyst Decision
  • MAIN Hold
  • GKOS Strong Buy
  • Analyst Count
  • MAIN 4
  • GKOS 12
  • Target Price
  • MAIN $59.75
  • GKOS $131.17
  • AVG Volume (30 Days)
  • MAIN 501.1K
  • GKOS 1.2M
  • Earning Date
  • MAIN 08-07-2025
  • GKOS 07-30-2025
  • Dividend Yield
  • MAIN 6.54%
  • GKOS N/A
  • EPS Growth
  • MAIN 13.61
  • GKOS N/A
  • EPS
  • MAIN 6.07
  • GKOS N/A
  • Revenue
  • MAIN $558,286,000.00
  • GKOS $432,953,000.00
  • Revenue This Year
  • MAIN $3.83
  • GKOS $27.88
  • Revenue Next Year
  • MAIN $1.43
  • GKOS $27.76
  • P/E Ratio
  • MAIN $10.73
  • GKOS N/A
  • Revenue Growth
  • MAIN 8.13
  • GKOS 26.70
  • 52 Week Low
  • MAIN $47.00
  • GKOS $77.10
  • 52 Week High
  • MAIN $67.77
  • GKOS $163.71
  • Technical
  • Relative Strength Index (RSI)
  • MAIN 53.00
  • GKOS 55.37
  • Support Level
  • MAIN $64.73
  • GKOS $88.85
  • Resistance Level
  • MAIN $67.77
  • GKOS $91.35
  • Average True Range (ATR)
  • MAIN 1.21
  • GKOS 3.10
  • MACD
  • MAIN -0.24
  • GKOS 0.79
  • Stochastic Oscillator
  • MAIN 44.74
  • GKOS 95.44

About MAIN Main Street Capital Corporation

Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancing, and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants, and other securities of the lower middle market and middle market companies based in the United States. Business functioned through the U.S. region and it derives the majority of its income from the source of fees, commission, and interest.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: